Abstract: The present disclosure relates to lipid nanoparticles comprising a lysophosphatidylcholine (LPC) compound and at least one further lipid, and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells. The present disclosure also relates to compositions comprising lipid nanoparticles comprising a LPC and at least on further lipid, in which the compositions comprise one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.

Abstract: Angiotensin II therapy has been found to increase mean arterial pressure in patients with catecholamine-resistant vasodilatory shock. Secondary analysis of the dataset from the Angiotensin II for the Treatment of High-Output Shock 3 (ATHOS-3) Study demonstrates that serum renin concentration is markedly elevated in some patients with catecholamine-resistant vasodilatory shock. This Invention relates to a method for identifying a subset of patients with elevated serum renin levels who gain a survival advantage when treated with angiotensin II. The invention therefore provides a method for diagnosis and treatment of catecholamine-resistant vasodilatory shock.

Abstract: The present disclosure relates to lysophosphatidylcholine (LPC) compounds and uses thereof in hyperactivating mammalian dendritic cells, such as human dendritic cells or canine dendritic cells. The present disclosure also relates to compositions comprising a LPC and one or more of a pathogen recognition receptor agonist, an antigen, and mammalian dendritic cells, as well as methods for production and use of the compositions.

Abstract: The present application provides enhanced antigen presenting cells comprising an agent that enhances the viability and/or function of the antigen presenting cell and/or an antigen and/or an adjuvant, methods of manufacturing such modified antigen presenting cells, and methods of using such modified antigen presenting cells, such as for modulating an immune response in an individual.

Abstract: A computing device for use in decision tree computation is provided. The computing device may include a software program executed by a processor using portions of memory of the computing device, the software program being configured to receive user input from a user input device associated with the computing device, and in response, to perform a decision tree task. The computing device may further include a decision tree computation device implemented in hardware as a logic circuit distinct from the processor, and which is linked to the processor by a communications interface. The decision tree computation device may be configured to receive an instruction to perform a decision tree computation associated with the decision tree task from the software program, process the instruction, and return a result to the software program via the communication interface.

Abstract: A computing device for use in decision tree computation is provided. The computing device may include a software program executed by a processor using portions of memory of the computing device, the software program being configured to receive user input from a user input device associated with the computing device, and in response, to perform a decision tree task. The computing device may further include a decision tree computation device implemented in hardware as a logic circuit distinct from the processor, and which is linked to the processor by a communications interface. The decision tree computation device may be configured to receive an instruction to perform a decision tree computation associated with the decision tree task from the software program, process the instruction, and return a result to the software program via the communication interface.